US2010197646A1PendingUtilityA1
Solvent-based sterilisation of pharmaceuticals
Est. expiryFeb 19, 2022(expired)· nominal 20-yr term from priority
A61K 9/14Y10T428/2982A61K 9/0078A61P 11/06A61L 2/022A61L 2/18A61L 2/02A61L 2103/05
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.
Claims
exact text as granted — not AI-modified1 - 76 . (canceled)
77 . A method for preparing sterile budesonide comprising:
(i) dissolving non-sterile budesonide in a solvent to form a non-sterile budesonide solution; (ii) filtering the non-sterile budesonide solution with a sterile filter to produce a sterile budesonide solution; and (iii) removing the solvent from the sterile budesonide solution to produce a sterile budesonide powder.
78 . The method as defined in claim 77 wherein the sterile filter has a pore size of 0.2 μm or less.
79 . The method of claim 77 further comprising the step of reducing the particle size of the sterile budesonide powder to a mass mean diameter of less than 10 μm.
80 . The method of claim 79 wherein the particle size of the sterile budesonide powder is reduced to a mass mean diameter of 1-5μm.
81 . The method of claim 80 wherein the particle size of the sterile budesonide powder is reduced to a mass mean diameter of 2-3μm.
82 . The method of claim 77 wherein the steps of the method are conducted under low oxygen conditions.
83 . The method of claim 77 wherein the steps of the method are conducted under vacuum conditions.
84 . The method of claim 77 wherein the steps of the method are conducted under nitrogen conditions.
85 . The method of claim 77 wherein the steps of the method are protected from light.
86 . The method of claim 77 further comprising the step of packaging the sterile budesonide powder.
87 . The method of claim 86 wherein the step of packaging the sterile budesonide powder is performed under sterile conditions.
88 . The method of claim 77 wherein step (i) is conducted at room temperature.
89 . The method of claim 77 further comprising the step of heating the solvent to 30-50° C. prior to dissolving the non-sterile budesonide.
90 . The method of claim 77 wherein the solvent is removed under reduced pressure.
91 . The method of claim 77 wherein the solvent is removed under vacuum conditions.
92 . The method of claim 77 wherein the solvent is removed at a temperature of 40° C. or less.
93 . The method of claim 77 further comprising the step of combining the sterile budesonide powder with a pharmaceutically acceptable carrier.
94 . The method of claim 93 wherein the pharmaceutically acceptable carrier is sterile water.
95 . The method of claim 77 wherein the solvent is a Class 2 solvent selected from the group consisting of acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, dichloromethane, 1,2-dimethoxyethane, 1,4-dioxane, 2-ethoxyethanol, ethyleneglycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, tetrahydrofuran, toluene, 1,2-trichloroethene and xylene.
96 . The method of claim 77 wherein the solvent is a Class 3 solvent selected from the group consisting of acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, ethanol, ethyl acetate, ethyl ether, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, methylisobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 2-pentanol, 2-propanol, and propyl acetate.
97 . The method of claim 77 wherein the solvent comprises an alcohol.
98 . The method of claim 97 wherein the alcohol is ethyl alcohol, methyl alcohol or isopropyl alcohol.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.